Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein

BACKGROUND: Oncologic patients who are extreme responders to molecularly targeted therapy provide an important opportunity to better understand the biologic basis of response and, in turn, inform clinical decision making. Malignant neoplasms with an uncertain histologic and immunohistochemical chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Westin, Shannon N, Wang, Kai, Araujo, Dejka, Wang, Wei-Lien, Miller, Vincent A, Ross, Jeffrey S, Stephens, Phillip J, Palmer, Gary A, Ali, Siraj M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896681/
https://www.ncbi.nlm.nih.gov/pubmed/24422672
http://dx.doi.org/10.1186/1756-8722-7-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896681/
https://www.ncbi.nlm.nih.gov/pubmed/24422672
http://dx.doi.org/10.1186/1756-8722-7-8

Ejemplares similares